Weill Cornell Medicine researchers have received major new funding to support collaborative efforts spanning clinical trials, precision medicine and drug target discovery with the potential to improve outcomes for patients with challenging cancers.
The Parker Institute for Cancer Immunotherapy (PICI) announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer.
